Inspiro Medical
Dry Powder Inhaler
Company Overview
Snapshot
Founded in November 2010 by Guy Steuer, Inspiro Medical operates with 1–10 employees. The company was acquired by OPKO Health in April 2014, marking a significant exit in the medical device sector.
Business overview
Inspiro Medical is a medical device company focused on developing an inhalation platform for delivering small molecules, such as corticosteroids or beta agonists, and macromolecules like antibodies or vaccines. Its core product, Inspiromatic, is a dry powder inhaler (DPI) designed to overcome the limitations of existing inhalers by combining an active dry powder fluidization mechanism with real-time feedback control and a data logger. This technology aims to ensure optimal drug delivery, particularly benefiting young children and the elderly. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Drug Delivery markets.
Strategic signal
In April 2014, Inspiro Medical was acquired by OPKO Health for $10 million. This acquisition highlights the strategic value of Inspiro Medical's innovative dry powder inhaler technology and its potential to enhance drug delivery solutions within the pharmaceutical industry. The deal signaled a successful exit for the startup and validated its approach to improving patient adherence and treatment efficacy, particularly for respiratory conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is Inspiro Medical's primary product?
- Inspiro Medical's primary product is Inspiromatic, a dry powder inhaler (DPI) designed to deliver small molecules and macromolecules with optimal drug delivery through an active dry powder fluidization mechanism and real-time feedback control.
- When was Inspiro Medical founded?
- Inspiro Medical was founded in November 2010.
- Who acquired Inspiro Medical?
- Inspiro Medical was acquired by OPKO Health in April 2014.
- What was the acquisition amount for Inspiro Medical?
- OPKO Health acquired Inspiro Medical for $10 million in April 2014, as reported by Globes and MobiHealthNews.
- What was a key milestone for Inspiro Medical prior to its acquisition?
- In June 2013, Inspiro Medical completed a successful first clinical trial in asthmatic children, demonstrating the efficacy of its smart inhaler technology.